Cancer Research Technology
Log in Register
Menu

Anti-p53 [Pab DO-7]
RECENTLY UPDATED

Invented by David Lane at University of Dundee

Info

Catalogue Number 151293
Applications
RECENTLY UPDATED
ELISA FACS IHC IF WB
Antigen/Gene or Protein Targets p53 (N terminus)
Reactivity Human
Relevance
RECENTLY UPDATED
Anti p53 monoclonal antibody used to analyse and detect ‘the most mutated gene in cancer’ p53, enabling identification of transformed cell lines.

Background and Research Application
Anti-p53 binds p53 protein, a crucial tumour suppressor protein implicated in over 50% of cancers. p53 is a stress-regulated transcription factor that regulates cell cycle arrest and was first identified as an SV40 large T antigen-binding protein. p53 is involved in many mechanisms of anti-cancer function, and plays a role in apoptosis, genomic stability, cell cycle regulation and inhibition of angiogenesis. p53 is known as the guardian of the genome as it functions to prevent gene mutation. Mutants of p53 which frequently occur in human cancers fail to recognise their DNA binding site, leading to the loss of tumour suppressor activity. p53 is typically found in low levels in healthy cells due to its short half-life, however in disease states it is expressed in high amounts due to somatic mutations and believed to contribute to transformation and malignancy. p53 mutations are found in over 50% of cancers with germline mutations, offering a predisposition to inherited cancer susceptibility syndrome.
Understanding the functions of mutant p53 can help in the development of new therapeutic approaches that may be useful in a broad range of cancer types.
This antibody was created in by David Lane, who also discovered p53, to measure p53 in various analyses of different tissue samples.
Host Mouse
Immunogen UniProt ID
RECENTLY UPDATED
P04637
Positive Control MDA-MB-231 cell line
Subclass IgG2b
Molecular Weight (kDa) 53
Recommended Growing Conditions DMEM + 5% FCS
Notes
RECENTLY UPDATED
Original Antibody Development
Bacterial expression systems were used to produce fragments of human p53 to isolate and characterise monoclonal antibodies. Splenocytes from BALB/c mice hyper immunised with recombinant human p53 were fused with a mouse myeloma line X63Ag8.653 with PEG as a fusogen.

Production Details
Purified using multi-step affinity chromatography with protein A.

Storage Conditions
Store at -20 degrees frozen. Avoid repeated freeze/thaw cycles.

Points of Interest
Immunocytochemistry (ICC) 1:20-1:200

Flow Cytometry (FACS) Assay Dependent

Immunofluorescence (IF) 1:20-1:200

Immunohistochemistry (Paraffin) (IHC (P)) 1:100 - 200

Immunoprecipitation (IP) 1:50-1:100

Western Blot (WB) 1:50-1:200

Anti-p53 reacts very strongly with p53 in conventionally fixed and processed histological sections. It allows for analysis of p53 expression in human tumours, including IHC on paraffin-embedded specimens. Anti-p53 antibody can be used on frozen sections as well as methacarn or formol saline fixed paraffin sections.

Concentration
1mg/ml as standard

Difference Between Clones
All clones were created at the same time as anti-p53 DO-7, and all bind to p53 protein, confirmed via immunoblotting, immunoprecipitation and immunocytochemistry. DO1 secreted large amounts of an IgG2a antibody whilst DO2 and DO7 secreted large amounts of an IgG2b antibody. It is likely DO-2 recognises a denatured epitope.
Research Area Apoptosis and Programmed Cell Death, Cancer, Cell Cycle, DNA Damage and Repair, Epigenetics & Nuclear Signalling

References

There are 18 reference entries for this reagent.

View All References

References: 18 entries
RECENTLY UPDATED

Grass et al. 2019. Leuk Lymphoma. 60(4):886-893. PMID: 30457458.

Kanda et al. 2018. BMC Cancer. 18(1):657. PMID: 29907137.

Murnyák et al. 2017. Oncotarget. 8(28):46348-46362. PMID: 28654422.

Gavressea et al. 2017. Anticancer Res. 37(6):2947-2957. PMID: 28551632.

IHC

The Prognostic Value of the Immunohistochemical Expression of Phosphorylated RB and p16 Proteins in Association with Cyclin D1 and the p53 Pathway in a Large Cohort of Patients with Breast Cancer Treated with Taxane-based Adjuvant Chemotherapy.

Europe PMC ID: 28551632

İlhan et al. 2016. J Vet Diagn Invest. :. PMID: 27016721.

Expression of p53 protein, Jaagsiekte sheep retrovirus matrix protein, and surfactant protein in the lungs of sheep with pulmonary adenomatosis.

Europe PMC ID: 27016721

Alsafadi et al. 2016. Oncotarget. 7(11):12331-43. PMID: 26575022.

Tajima et al. 2015. Pathol Int. :. PMID: 25855894.

A signet-ring cell melanoma arising from a medium-sized congenital melanocytic nevus in an adult: A case report and literature review.

Europe PMC ID: 25855894

Ko et al. 2012. Pathol Int. 62(1):43-8. PMID: 22192803.

Primary pure squamous cell carcinoma of the thyroid: report and histogenic consideration of a case involving a BRAF mutation.

Europe PMC ID: 22192803

Molenaar et al. 2009. Proc Natl Acad Sci U S A. 106(31):12968-73. PMID: 19525400.

Inactivation of CDK2 is synthetically lethal to MYCN over-expressing cancer cells.

Europe PMC ID: 19525400

Stephen et al. 1995. J Mol Biol. 248(1):58-78. PMID: 7537340.

Characterisation of epitopes on human p53 using phage-displayed peptide libraries: insights into antibody-peptide interactions.

Europe PMC ID: 7537340

Vojtĕsek et al. 1992. J Immunol Methods. 151(1-2):237-44. PMID: 1378473.

An immunochemical analysis of the human nuclear phosphoprotein p53. New monoclonal antibodies and epitope mapping using recombinant p53.

Europe PMC ID: 1378473


Add a reference

References: 18 entries
RECENTLY UPDATED

Grass et al. 2019. Leuk Lymphoma. 60(4):886-893. PMID: 30457458.

Kanda et al. 2018. BMC Cancer. 18(1):657. PMID: 29907137.

Murnyák et al. 2017. Oncotarget. 8(28):46348-46362. PMID: 28654422.

Gavressea et al. 2017. Anticancer Res. 37(6):2947-2957. PMID: 28551632.

IHC

The Prognostic Value of the Immunohistochemical Expression of Phosphorylated RB and p16 Proteins in Association with Cyclin D1 and the p53 Pathway in a Large Cohort of Patients with Breast Cancer Treated with Taxane-based Adjuvant Chemotherapy.

İlhan et al. 2016. J Vet Diagn Invest. :. PMID: 27016721.

Expression of p53 protein, Jaagsiekte sheep retrovirus matrix protein, and surfactant protein in the lungs of sheep with pulmonary adenomatosis.

Alsafadi et al. 2016. Oncotarget. 7(11):12331-43. PMID: 26575022.

Tajima et al. 2015. Pathol Int. :. PMID: 25855894.

A signet-ring cell melanoma arising from a medium-sized congenital melanocytic nevus in an adult: A case report and literature review.

Ko et al. 2012. Pathol Int. 62(1):43-8. PMID: 22192803.

Primary pure squamous cell carcinoma of the thyroid: report and histogenic consideration of a case involving a BRAF mutation.

Molenaar et al. 2009. Proc Natl Acad Sci U S A. 106(31):12968-73. PMID: 19525400.

Inactivation of CDK2 is synthetically lethal to MYCN over-expressing cancer cells.

Stephen et al. 1995. J Mol Biol. 248(1):58-78. PMID: 7537340.

Characterisation of epitopes on human p53 using phage-displayed peptide libraries: insights into antibody-peptide interactions.

Vojtĕsek et al. 1992. J Immunol Methods. 151(1-2):237-44. PMID: 1378473.

An immunochemical analysis of the human nuclear phosphoprotein p53. New monoclonal antibodies and epitope mapping using recombinant p53.


Add a reference